A randomized controlled trial [15] found evidence to suggest that adipose tissue may be a primary source of circulating ZAG in humans and that the downregulation of ZAG expression in adipose tissue may be responsible for the reduced circulating ZAG levels in T2DM patients. The gene discussed is AZGP1; the disease is type 2 diabetes mellitus.